Rebecca Byam Buys 14,235 Shares of HCW Biologics (NASDAQ:HCWB) Stock

HCW Biologics Inc. (NASDAQ:HCWB) CFO Rebecca Byam acquired 14,235 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were acquired at an average cost of $1.41 per share, with a total value of $20,071.35. Following the purchase, the chief financial officer directly owned 57,245 shares of the company’s stock, valued at $80,715.45. This trade represents a 33.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

HCW Biologics Stock Performance

NASDAQ:HCWB opened at $2.09 on Friday. The firm has a market capitalization of $14.07 million, a price-to-earnings ratio of -0.22 and a beta of 1.13. HCW Biologics Inc. has a 52-week low of $0.25 and a 52-week high of $8.75. The stock has a fifty day moving average of $0.74 and a 200 day moving average of $1.14.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.81. The company had revenue of $6.54 million during the quarter, compared to analyst estimates of $6.54 million. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Maxim Group lifted their price objective on HCW Biologics from $2.00 to $5.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen raised HCW Biologics to a “hold” rating in a research note on Saturday, May 23rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC acquired a new position in HCW Biologics Inc. (NASDAQ:HCWB) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.96% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.